On 12 Nov 2026 HCA Healthcare closed at $500.66, +7.8% this year; market cap $108.75bn, P/E 16.1.
Health Care · Health Care Facilities · NYSE · United States
HCA Healthcare, Inc., through its subsidiaries, provides health care services in the United States. The company owns, manages, and operates hospitals, ASCs, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, radiation and oncology therapy centers, as well as rehabilitation and physical therapy centers, physician practices, home health agencies, hospices, outpatient physical therapy providers, home and community-based services providers, and various other facilities. Its general and acute care hospitals offer medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic services, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.
| Market cap | $108.75bn |
| P/E (trailing) | 16.1 |
| EPS (TTM) | $31.20 |
| Beta | 1.10 |
| Dividend | $3.12 |
| Dividend yield | 0.62% |
| Ex-dividend date | 15 Dec 2026 |
| Latest report | 27 Oct 2026 |
| Next earnings | 26 Jan 2027 |
| YTD | +7.8% |
| 1Y | +6.4% |
| 3Y | +30.6% |
| 5Y | +16.3% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $75.60bn | $6.78bn | $7.69bn |
| 2024 | $70.60bn | $5.76bn | $5.64bn |
| 2023 | $64.97bn | $5.24bn | $4.69bn |
| 2022 | $60.23bn | $5.64bn | $4.13bn |
| 2021 | $58.75bn | $6.96bn | $5.38bn |
We publish no single base value for HCA Healthcare. Our valuation methods put it between $326.91 and $436.73 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.